KATHRYN F. McGONIGLE, M.D. - Women's Cancer Care of Seattle

KATHRYN F. McGONIGLE, M.D.
Women’s Cancer Care of Seattle
Gynecologic Oncology
1560 North 115 th St.
Medical Office Building Suite 101
Seattle, WA 98133
Telephone: 206-368-6806
FAX: 206-368-6808
EDUCATION
Fellowship Gynecologic Oncology University of California
1991-1993 Los Angeles, California
Residency Obstetrics and Gynecology University of California
1985-1988 San Francisco, California
Internship Obstetrics and Gynecology University of California
1984-1985 San Francisco, California
Medical M.D., Cum Laude St. Louis University School
1980-1984 St. Louis, Missouri
Graduate M.P.H. Environmental Health University of California
Sciences Berkeley, California
1978-1979
Undergraduate B.S. Chemical Engineering University of Notre Dame
1974-1978 Notre Dame, Indiana
MEDICAL LICENSURE
Washington MD00040252 2001-current
California #G56552 1985-2001
Maryland #D37385 1988-1991

BOARD CERTIFICATION
National Boards Part I, II, III 1982-1985
General Board Certification OB/Gyn No. 88-4774-050554 1988
General Board OB/Gyn oral examination 1990
Gynecologic Oncology written certifying examination 1994
Gynecologic Oncology oral examination 1997
General OB/Gyn and Gynecologic Oncology recertification 2000-2010
ACADEMIC APPOINTMENTS
2009-Present Clinical Associate Professor
Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
2001-2009 Clinical Assistant Professor
Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Washington
Seattle, WA
1997-2001 Assistant Professor
Gynecologic Oncology
Department of Obstetrics and Gynecology
UCLA School of Medicine
Los Angeles, California
1994-1997 Assistant Adjunct Professor
Department of Obstetrics and Gynecology
University of California, Irvine
Irvine, California
1993-1997 Staff Surgeon
Department of Gynecology
City of Hope National Medical Center
Duarte, California
1991-1993 Clinical Instructor
Department of Obstetrics and Gynecology
UCLA Medical School
Los Angeles, California
2

1988-1991 Clinical Instructor
Department of Obstetrics and Gynecology
Johns Hopkins University School of Medicine
Francis Scott Key Medical Center
Baltimore, Maryland
PROFESSIONAL ACTIVITY
Awards and Honors
2010 Seattle Metropolitan Magazine: Voted as Top Doctor: Gynecologic
Oncology
2009 Seattle Metropolitan Magazine: Voted as Top Doctor: Gynecologic
Oncologist Surgeon and Oncologist
2009-10 Seattle Magazine: Voted as Best Doctor Gynecologic Oncologist
2009 American Biographical Institute Inc. 2009 Woman of the Year in
Medicine and Healthcare Award
2008 Washington State’s Best Doctors: Listed in Washington Travel and
Life Magazine
2008 Seattle Metropolitan Magazine: Golden Stethescope Award
Gynecologic Oncology
2006-2010 Best Doctors in America
2007 America’s Top Oncologist
2001 Teaching award of appreciation: UCLA Gynecologic Oncology
Fellows (1997-2001)
1999 Teaching award of appreciation: UCLA OB/GYN Resident Class
1999 WAGO James Nolan Award: best presentation by WAGO member
1991 American Cancer Society Clinical Oncology Fellowship Award
1984 American Medical Women’s Association - Jane Glasgow Award
1984 Florent Franks Award in Physiology
1984 Randal Meglitsch Award in Obstetrics and Gynecology
1983 AOA Medical Society
1978 Tau Beta Pi Engineering Honor Society, Dean’s Honor List
Contracts, Grants and Research Awards
2005-current Principal Investigator: Phase II Study of Weekly Topotecan
with Bevacizumab in Platinum Resistant Recurrent Ovarian,
Fallopian Tube and Primary Peritoneal Cancers: Supported
by Glaxo Smith Kline (drug and financial), and Genentech
(drug only)
2005-2007 Gynecologic Oncology Group
Virginia Mason Medical Center Institutional Principal
Investigator
3

1994-1997 Tamoxifen and Uterine Effects: A Prospective Study
City of Hope Breast Cancer Initiative Seed Grant
Kathryn F. McGonigle, M.D., P.I.
$34,000
1994-1997 Gynecologic Oncology Group
City of Hope Institutional Principal Investigator
1990-1995 Hormone replacement therapy in postmenopausal women
ages 65 and older: clinical side effects and efficacy.
Francis Scott Key Institutional Grant
CERT Chesapeake Education Research Training
Kathryn F. McGonigle, M.D., Co-PI
$5,000.00
Service to Professional Societies:
2004-2005 Seattle Gynecologic Society, Program Chair
1996-2000 Gynecologic Oncology Group, Endometrial Committee
1994-2000 Southwest Oncology Group (SWOG) Gynecologic Cancer
Committee
1994-1996 Consultant, National Surgical Adjuvant Breast and Bowel
Project (NSABP) for Endometrial Screening for Breast
Cancer Prevention Trial (BCPT)
Membership in Professional Organization
1990 – Present American College of Obstetricians and Gynecologists
(ACOG) - Fellow
1991 – 1993 American Cancer Society (ACS)
1992 – 1998 American College of Surgeons (ACS) - Associate Member
1993 – Present Society of Gynecologic Oncologists (SGO)
1993 – Present Gynecologic Oncology Group
1993 – 2000 Los Angeles Obstetrical and Gynecological Society
1994 – 2000 Southwest Oncology Group (SWOG) - Gynecologic
Cancer Committee
1995 – 1997 Society of Surgical Oncology (SSO)
1995 – 1997 Los Angeles Surgical Society
1998 – Present Western Association of Gynecologic Oncologists (WAGO)
2001 – Present Seattle GYN Society
2001 – 2007 American Medical Association
4

2001 – Present King County Medical Society
2001 – Present Washington State Medical Association
2001 – Present Puget Sound Oncology Consortium
UNIVERSITY AND PUBLIC SERVICE
Hospital
Northwest Hospital and Medical Center
Seattle, WA
2008- Current Gynecologic Tumor Committee
Virginia Mason Medical Center
Seattle, WA
2001- Current Gynecologic Tumor Committee
2002- 2007 Gynecologic M&M Committee (Chair)
UCLA Medical Center
Los Angeles, California
1999 – 2001 Internal Scientific Peer Review Committee (ISPRC)
1997 – 2001 Quality Assurance Committee
1998 – 2001 Cancer Committee
City of Hope National Medical Center
Duarte, California
1993 – 1997 Continuing Medical Education Committee
1993 – 1997 Institutional Review Board
1995 – 1997 Nutrition Support Committee
Francis Scott Key Medical Center
Baltimore, Maryland
1988 – 1991 Patient Care Committee
1988 – 1991 Credentialing Committee
1989 – 1991 Laser Safety Committee
1990 – 1991 Endoscopic Surgical Committee
Journal Reviewer
1998 – Present Reviewer for Gynecologic Oncology
5

1998 – Present Reviewer for Fertility and Sterility
1995 – Present Reviewer for Gynecologic Techniques
1995 – Present Reviewer for Obstetrics and Gynecology
2006 – Present Reviewer for International Journal Gynecological Cancer
Community
Cancer and Genetic Risks, Northwest Hospital Grand Rounds, Seattle, WA,
January 25,2011. (upcoming)
Ask the Doctor about Gynecolologic Cancer, Gilda’s Club Seattle, WA January
20, 2011. (upcoming)
Robotic Surgery: Is it Fad or For Real?, Cancer Life Line, Northwest Hospital,
Seattle, WA September, 2010.
Robotic Surgery Fad or Fiction, Mensa Group, Redmond, WA, May, 2010.
Prevention of Gynecologic Malignancies. AIDS Project LA. Los Angeles, CA,
November 20, 1998.
Gynecologic Effects of Breast Cancer Therapies: Breast Cancer Support Group,
UCLA, Los Angeles, California, September 22, 1998.
Women and Cancer: An Update on Ovarian Cancer: Santa Monica-UCLA
Women’s Lecture Series, Santa Monica, CA, May 18, 1998.
Gynecologic Effects of High Dose Chemotherapy: Breast Cancer Support Group,
Sherman Oaks, California, November 20, 1996.
Tamoxifen Effect: Breast Cancer Support Group, UCLA, Los Angeles, California,
1994.
Gynecologic Effects of DES: Los Angeles DES Daughters, Los Angeles,
California, 1992.
PUBLICATIONS
Book Chapters
1. McGonigle KF, Huggins GR. Oral contraceptives and breast disease. In:
Stoll BA, ed. Approaches to Breast Cancer Prevention. Netherlands:
Kluwer Academic Publishers, 1991.
6

2. McGonigle KF, Lagasse LD, Karlan BY. Ovarian, uterine and cervical
cancer in the elderly woman. In: Kaider FE, ed. Clinics in Geriatric
Medicine. Philadelphia: WB Saunders Co., 1993
3. Huggins GR, McGonigle KF, Zucker P. Oral contraceptive use and
neoplasia. In: Wallach EE, Zacur HA, eds. Reproductive Medicine and
Surgery. St. Louis: Mosby-Year Book, 1995.
4. McGonigle KF, Huggins GR. Choosing hormonal contraception. In: Stoll
BA, ed. Reducing Breast Cancer Risk in Women. Netherlands: Kluwer
Academic Publishers, 1995.
5. McGonigle KF. Radiation associated bowel complications. In: Vasilev
SA, ed. Perioperative Care in Gynecologic Oncology: Evidence-Based
Management. John Wiley and Sons, 2000.
6. McGonigle KF, Lagasse LD. Perioperative care in the management of
vulvar cancer. In: Vasilev SA, ed. Perioperative care in gynecologic
oncology: Evidence-Based Management. John Wiley and Sons, 2000.
7. Kupferman S, McGonigle KF. Evaluation of Adnexal Masses &
Screening for Ovarian Cancer. In: Lemcke D, Pattison J, Marshal LA,
Cowley DS, eds. Current Care of Women: Diagnosis and Treatment.
Lange Medical Books, McGraw-Hill, New York, 2004.
BOOK REVIEWS
McGonigle KF Reviewed book entitled, “Endometrial Carcinoma and
Precursors: Diagnosis and Treatment.” Mencaglia L, Valle RF and Lurain J (eds)
– ISIS Medical Media Limited – Oxford, England – Oncology 14(1):116.
Journal Articles, Peer Reviewed
1. Golbus MS, McGonigle KF, Goldberg JD, Filly RA, Callen PW, Anderson
RL. Fetal tissue sampling: the San Francisco experiences of 190
pregnancies. West J Med 150:423, 1989.
2. McGonigle KF, Huggins GR. Oral contraceptives and breast disease.
Fertil Steril 56:799, 1991.
3. McGonigle KF, Dudzinski MR. Case Report: endometrial carcinoma of
the ovary presenting with an enlarged inguinal lymph node without
evidence of abdominal carcinomatosis. Gynecol Oncol 45:225, 1992.
7

4. McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd
HL. Development of endometrial cancer in women on estrogen and
progestin hormone replacement therapy. Gynecol Oncol 55:126, 1994.
5. Vasilev SA, McGonigle KF, Spencer-Smith L. Intestinal peritoneal sling
as an adjuvant to radical pelvic surgery and/or adjuvant irradiation. J Am
Coll Surg 180:568, 1994.
6. Vasilev SA, McGonigle KF. Extraperitoneal laparoscopic para-aortic
lymph node dissection in a pig model: development of a technique. J
Lapar Surg 5(2):85, 1995.
7. McGonigle KF, Lavey RH, Juillard GJF, Berek JS: Complications of
radiation therapy for gynecologic malignancies in elderly women. Int J
Gyn Cancer 6:149, 1996.
8. McGonigle KF, Lantry SA, Odom-Maryon TL, Chai Akiko, Vasilev SA,
Simpson JF: Histopathologic effects of tamoxifen on the uterine epithelium
of breast cancer patients: analysis by menopausal status. Cancer Letters
101:59, 1996.
9. Vasilev SA, McGonigle KF: Extraperitoneal laparoscopic para-aortic
lymph node dissection. Gynecol Oncol 61:315, 1996.
10. McMeekin DS, McGonigle KF, Vasilev SA. Cervical cancer prevention:
Toward cost-effective screening. Medscape Women’s Health 2(12), 1997.
11. McGonigle KF, Shaw S, Vasilev SA, Odom-Maryon TL, Roy S, Simpson
JF. Abnormalities detected on transvaginal ultrasonography in tamoxifentreated
postmenopausal breast cancer patients may represent
endometrial cystic atrophy. Am J Obstet Gynecol 178(6):1145-50, 1998.
12. Morgan RJ, Newman EM, Doroshow JH, McGonigle KF, Margolin K
Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V,
Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B,
Yen Y, Klevecz R. Phase I trial of intraperitoneal iododeoxyuridine with
and without intravenous high-dose folinic acid in the treatment of
advanced malignancies primarily confined to the peritoneal cavity: flow
cytometric and pharmacokinetics analysis. Cancer Res. 1998;58:2793-
800.
13. Gil B, Simpson JF, Somlo G, McGonigle KF, Wilczynski SP. Effects of
tamoxifen on the cytology of the uterine cervix in breast cancer patients.
Diagn Cytopath 19:417-422, 1998.
8

14. Monk BJ, Fowler JM, Burger RA, McGonigle KF, Eddy GI, Montz FJ.
Expanded polytetrafluoroethylene is an effective barrier in preventing
pelvic adhesions after radical surgery for ovarian carcinoma. Int J Gynecol
Oncol 8:403-408, 1998
15. McGonigle KF, Vasilev SA, Odom-Maryon TL, Simpson JF. Ovarian
histopathology in breast cancer patients receiving tamoxifen. Gynecol
Oncol 73:402-406, 1999.
16. Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL,
Creasman WT. An experience with estrogen replacement therapy in
breast cancer survivors. Int J Fertil 44(4):186-192, 1999.
17. Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S,
Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate
J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y. Phase II trial of
high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with
autologous stem cell support in patients with residual or responding
recurrent ovarian cancer. Bone Marrow Transplant 28(9):859-63, 2001.
18. O’Connel JT, Tomlinson JS, Roberts AA, McGonigle KF, Barsky SH.
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
Am J Pathol 161(2):551-64, 2002.
19. Elkas JC, Holschneider CH, Katz B, Li AJ, Pharm RL McGonigle KF,
Berek JS. The use of continuous infusion topotecan in persistent and
recurrent ovarian cancer. Int J. Gynecol CA 13:138-141, 2003.
20. Muntz H, Goff B, McGonigle KF, Isaacson C. The significance of
psommoma bodies in screening cervical cytologic smears. Am J Obset
Gynecol 188:1609-14,2003.
21. Morgan RJ, Synold T, Gandara D, Muggia F, Scudder S, Reed E,
Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S,
McGonigle KF, Longmate J, Yen Y, Chow W, Somlo G, Carroll M,
Doroshow JH. Phase II trials of carboplatin and infusional cyclosporine
with or without alpha-interferon in recurrent ovarian, fallopian tube or
primary peritoneal cancer. Cancer Chemother Pharmacol 54:283-9, 2004.
22. Begley, JS, Kupferman, SP, Kuznetsov DD, Kobashi KC, Govier FE,
McGonigle KF, Muntz HG. Incidence and management of
sacrocolpopexy mesh erosions. Am J Obstet Gynecol 192:1956-62,2005.
23. Govier FE, Kobashi KC, Kozlowski PM, Kuznetsov DD, Begley SJ,
McGonigle KM, Muntz HG. High complication rate identified in
9

sacrocolpopexy patients attributed to silicone mesh. Urology 65:1099-
1103,2005.
24. Ellenhorn JDI, Smith DD, Schwartz RE, Kawachi MH, Wilson TG,
McGonigle KF, Wagman LD, Paz IB. Paint-only is equivalent to scruband-paint
in preoperative preparation of abominal surgery sites. J Am Coll
Surg 201:737-741,2005.
25. McGonigle KF, Smith DD, Marx HF, Morgan RJ, Vasilev SA, Roy S,
Morgan RJ, Wong PT, Simpson JF, Wilczynski SP. Uterine effects of
tamoxifen: a prospective study. Int J Gynecol Cancer. 16 (2): 814-820,
2006.
26. Morgan RJ, Synold TV, Gandara D, Muggia F, Scudder S, Reed R,
Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S,
McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M,
Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with
alpha-interferon in recurrent ovarian cancer: a California Cancer
Consortium Trial. Int J Gynecol Cancer. 17:373-378, 2007.
27. Muntz HG, Malpass TW, McGonigle KF, Robertson MD, Weiden PL.
Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy
ovarian and primary peritoneal carcinoma. Cancer. 113: 490-496, 2008
28. Rebeles, SA, Muntz HG, Wieneke-Broghammer C, Vason ES, McGonigle
KF. Robot-assisted total laparoscopic hysterectomy in obese and
morbidly obese women. J Robotic Surg. 3:141-147, 2009.
29. Goel, M, McGonigle KF, Vason E, Muntz HG. Leukocytosis after robotic
hysterectomy: commonly observed but clinically insignificant. J Robotic
Surg. 4: 235-239, 2010.
30. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE,
Goff BA, Gray HJ, Malpass TW. Combined weekly topotecan and
biweekly bevacizumab in women with platinum-resistant ovarian,
peritoneal, or fallopian tube cancer: results of a phase 2 study. In Press,
Cancer.
Journal Articles, Other (includes non-peer reviewed)
1. McGonigle KF, Huggins GR. Tubal sterilization: epidemiology of regret.
Contemp Obstet Gynecol 35:15, 1990.
2. McGonigle KF, Berek JS. Early-stage squamous cell and
adenocarcinoma of the cervix. Curr Opin Obstet Gynecol 4:109, 1992.
10

3. McGonigle KF. How oral contraceptives affect breast disease. Contemp
Obstet Gynecol 37:156, 1992.
4. McGonigle KF. How progestins reduce endometrial cancer risk in ERT
users. Contemp Obstet Gynecol 42:96-108, 1997.
5. Yamada SD, McGonigle KF. Cancer of the endometrium and corpus
uteri. Curr Opin Obstet Gynecol 10:57-60, 1998.
6. Chen LM, McGonigle KF, Berek JS. Endometrial Cancer: Recent
Developments in Evaluation and Treatment. Oncology 13:1665-1682,
1999
Letters to the Editor
1. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson
JF. Response to Letter to the Editor titled Ultrasonographic evaluation of
endometrial pathologies in postmenopausal breast cancer patients with
tamoxifen treatment) Response was to this article: Abnormalities
detected on transvaginal ultrasonography in tamoxifen-treated
postmenopausal breast cancer patients may represent endometrial cystic
atrophy. Am J Obstet Gynecol 178(6)1145-50, 1998.
IMAGES
1. Barsky SH, McGonigle K. Images in clinical medicine. Pseudomyxoma
peritonei. N Engl J Med 350: e13, 2004.
Abstracts and Posters
1. Bellantoni MF, Harman SM, Vittone JL, Bryant L, Bass KM, Cotrell E,
Copley CJ, McGonigle KF, Blackman MR. Android body habitus is
associated with decreased growth hormone secretion in postmenopausal
women. Oral presentation. The American Federation for Clinical
Research, Baltimore, Maryland, May 1992.
2. McGonigle KF, Karlan BY, Barbuto DA, Chen D, Lagasse LD, Judd HL.
Endometrial cancer developing in women on combination estrogen and
progestin therapy - a retrospective analysis. Post presentation. American
College of Obstetricians and Gynecologists (ACOG) Annual Meeting,
Washington, DC, May 1993.
3. McGonigle KF, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd
HL. Development of endometrial cancer on estrogen and progestin
11

hormone replacement therapy. Oral presentation. Western Association of
Gynecologic Oncologists (WAGO) Santa Monica, California, May 1993.
4. Bellantoni M, Vittone J, Bass K, McGonigle KF, Davidoff A, Haszard S,
Harman SM, Tobin J, Blackman M. Low dose daily estrogen and
progestin therapy in older postmenopausal women. Gerontological
Society of America 47th Annual Society Meeting, Atlanta, Georgia,
November 1994.
5. McGonigle KF, Simpson JF, Gill BL, Maryon TL, Wilzcynski SP, Vasilev
SA. Uterine pathology in breast cancer patients on Tamoxifen. American
Society of Clinical Oncology (ASCO), Dallas, Texas, May 1994.
6. Vasilev SA, McGonigle KF. Extraperitoneal laparoscopic para-aortic
lymph node dissection: development of a technique. Society of
Gynecologic Oncology (SGO), San Francisco, California, February 1995.
7. Morgan R, Kevecz R, Doroshow JH, Newman E, Carroll M, Coluzzi P,
Leong L, Shibata S, Chow W, Vsilev S, McGonigle KF. Effects of
intravenous (IV) calcium leucovorin (LV) on tumor cell incorporation of
intraperitoneal (IP) iododeoxyuridine (IudR): flow cytometric analysis.
American Society of Clinical Oncology (ASCO), Los Angeles, California,
May 1995.
8. McGonigle KF, Vasilev SA, Simpson JF. Ovarian pathology in breast
caner patients on Tamoxifen. American Society of Clinical Oncology
(ASCO), Los Angeles, California, May 1995.
9. Monk BJ, McGonigle KF, Spencer-Smith EL, Vasilev SA. Intestinal
peritoneal sling as an adjunct to radical pelvic surgery and pelvic
irradiation. Western Association of Gynecologic Oncologists (WAGO),
Coeur d’Alene, ID, June 1995.
10. Monk BJ, Fowler JM, Burger RA, McGonigle KF, Eddy GL, Montz FJ.
The Gore-Tex surgical membrane is effective in preventing pelvic
adhesions after radical surgery for ovarian cancer: Results of a controlled,
randomized, multicenter study. Western Association of Gynecologic
Oncologists (WAGO), San Diego, California, May 1996.
11. Morgan R, Dorowshow JH, Newman E, Carrol M, Coluzzi P, Leong L,
Shibata S, Chow W, Vasilev S, McGonigle KF, Margolin K, Somlo G,
Raschko J, Tetef M, et al. High dose VP16, cyclophosphamide, infusional
doxorubicin, with autologous bone marrow and peripheral blood stem cell
support in patients with ovarian cancer. American Society of Clinical
Oncology (ASCO), Los Angeles, California, May 1996.
12

12. McGonigle KF, Marx HF, Maryon TL, Roy S, Vasilev SA, Simpson JF.
The uterine effects of tamoxifen: a prospective study. Society of
Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
13. Brewster WR, Grosen E, Kyukendall JL, McGonigle KF, DiSaia PJ.
Estrogen replacement therapy in breast cancer survivors. Society of
Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
14. McGonigle KF, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness
of transvaginal ultrasound in detecting endometrial pathology in breast
cancer patients receiving tamoxifen. The American College of
Obstetricians and Gynecologists (ACOG), Las Vegas, Nevada, April 1997.
15. Brewster WR, Grosen E, Kuykendall JL, McGonigle KF, DiSaia PJ.
Estrogen replacement therapy in breast cancer survivors. Western
Association of Gynecologic Oncologists (WAGO), Jasper, Alberta,
Canada, June 1997.
16. McGonigle KF, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness
of transvaginal ultrasound in detecting endometrial pathology in breast
cancer patients receiving tamoxifen. Pacific Coast Obstetrical and
Gynecological Society, Coeur d’ Alene, Idaho, September 1997.
17. McGonigle KF, Vasilev SA, Maryon T, Simpson JF. Ovarian pathology in
breast cancer patients receiving tamoxifen. Western Association of
Gynecologic Oncologists (WAGO), Napa Valley, CA, May, 1998.
18. McGonigle KF, Marx HF, Morgan RJ, Maryon TL, Chen E, Roy S, Vasilev
SA, Wong, T, Roach L, Wilczynski SP, Simpson JF. Uterine effects of
tamoxifen: a prospective study. Western Association of Gynecologic
Oncologists (WAGO), 1999.
19. Reynolds CA, Holschneider CH, Natarjan S, Munro MG, Lemus J,
McGonigle KF. Toluidine blue for cervical cancer screening: a new use
for an old tool. Society of Gynecologic Oncologists (SGO), 2001.
20. Muntz HG, Goff B, McGonigle KF, Isaacson C. Significance of
Psommoma bodies in screening cervical cytology smears. Pacific Coast
OB/GYN Society, 2002.
21. Kuznetsov DD, Govier FE, Kobashi KC, Kozlowski PM, Begley SJ,
McGonigle KF, Muntz HG. A high vaginal erosion rate identified in
sacrocolpopexy patients using silicone mesh. Society of Urodynamics and
Female Urology, Scottsdale AZ, 2/27/04.
13

22. Muntz HG, McGonigle KF et al. Phase II study of intraperitoneal
topotecan as consolidative therapy in patients with advanced ovarian,
fallopian tube and peritoneal cancer. Western Association of Gynecologic
Oncologists (WAGO), May, 2004.
23. Muntz HG, McGonigle KF, Malpass TW, Robertson MD, Kamarauskiene
D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation
chemotherapy in patients with advanced ovarian and and primary
peritoneal cancer. Martha Rivkin Ovarian Cancer Research Meeting,
Seattle, WA, September, 2004.
24. Muntz HG, McGonigle KF, Malpass TW, Robertson MD, Kamarauskiene
D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation
chemotherapy in patients with advanced ovarian and and primary
peritoneal cancer. Society of Gynecologic Oncologists (SGO), March,
2005.
25. Muntz HG, McGonigle KF, Jacobs A, Malpass TW. Phase II trial of
weekly Docetaxel (Taxotere) as initial chemotherapy for advanced ovarian
cancer. Pacific Coast OB/GYN Society. September 2006
26. Muntz HG, McGonigle KF, Malpass TM, Robertson MD, Kamarauskiene
D, Weiden P. Phase II study of intraperitoneal topotecan in advanced
ovarian cancer. Cancer Investigation 24:39-41; 2006.
27. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ,
Malpass TW. Phase II prospective study of weekly topotecan and
bevacizumab in platinum refractory ovarian or primary peritoneal cancer.
American Society of Clinical Oncology (ASCO), May 2008.
28. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ,
Malpass TW. Phase II prospective study of weekly topotecan and
bevacizumab in platinum refractory ovarian or primary peritoneal cancer.
Western Association of Gynecologic Oncology (WAGO), June 2008.
29. McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ,
Malpass TW. Phase II prospective study of weekly topotecan and
bevacizumab in platinum refractory ovarian or primary peritoneal cancer.
Society of Gynecologic Oncologists (SGO), February 2009.
30. Rebeles, SA, Muntz HG, Wieneke-Broghammer C, Vason ES, McGonigle
KF. Robot-assisted total laparoscopic hysterectomy in obese and
morbidly obese women. Western Association of Gynecologic Oncology
(WAGO), June 2009.
14

31. Goel, M, McGonigle KF, Vason E, Muntz HG. Leukocytosis after robotic
hysterectomy commonly observed but clinically insignificant. Western
Association of Gynecologic Oncology (WAGO), June 2010.
Updated January 2011
15